Walpar Nutritions operates within a single business segment, focusing on the manufacturing and trading of pharmaceutical, nutraceutical, herbal, and Ayurvedic commodities. For the 2024-25 year, the company plans to expand its product line to meet the specific requirements of both the Indian and global markets. To support this expansion, the firm will increase its focus on dedicated research and development initiatives and aim for higher overall productivity. The company maintains a diverse portfolio of products and utilizes a wide network for sales, marketing, and distribution across various fill volumes. Management has adopted superior and advanced technology for producing its wide range of pharmaceutical, nutraceutical, Ayurvedic, and herbal products. Demonstrating its market performance, the company's total turnover for the financial year 2023-24 reached a significant ₹5144.38 Lakhs.;
CEO/MD
Kalpesh Pravinchandra Ladhawala